Pharmaceutical company Alvogen revealed on Wednesday the availability of its generic equivalent of Suboxone sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the US in 2mg/0.5 mg, 4mg/1mg, 8 mg/2mg and 12mg/3mg strengths.
The company said the Suboxone sublingual film is indicated for treatment of opioid dependence.
Based on Indivior SEC Filings, the US sales for Suboxone were approximately USD1.1bn in 2018.
Suboxone, which is a registered trademark of Indivior UK LLC, follows the issuance of a mandate from the US Court of Appeals for the Federal Circuit vacating the preliminary injunction that had been granted enjoining Dr. Reddy's Laboratories from marketing its product.
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets